$a$

| 0 6 12 18 24 48(hr) | 0 6 12 18 24(hr) |
| --- | --- |
| Caspase-9 | 47kDa |
| Caspase-3 | 32kDa |
| Caspase-8 | 44/40kDa |
| Actin | 23kDa |

MNNG/ADR

WE-68/ADR

$b$

| Flavopiridol (200nM) | - | - | - | - | + | + | + | + |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Z-VAD-FMK (75μM) | - | + | - | - | - | + | - | - |
| Z-IETD-FMK (75μM) | - | - | + | - | - | - | + | - |
| Z-DEVD-FMK (50μM) | - | - | - | + | - | - | - | + |

$c$

| Flavopiridol (200nM) | - | + | + | + | + |
| --- | --- | --- | --- | --- | --- |
| Z-VAD-FMK (75μM) | - | - | + | - | - |
| Z-IETD-FMK (75μM) | - | - | - | + | - |
| Z-DEVD-FMK (50μM) | - | - | - | - | + |

Cleaved PARP

Caspase-3

Actin

$a$

| Flavopiridol (nM) | 0 | 400 | 0 | 400 |
| --- | --- | --- | --- | --- |
| Cytochrome c (cytosol) |  |  |  |  |
| Actin |  |  |  |  |
| MNNG |  |  |  |  |
| WE-68 |  |  |  |  |

$b$

| MNNG/ADR | WE-68/ADR |
| --- | --- |
| P53 |  |
| Bax |  |
| Bcl-xL |  |
| Bcl-2 |  |
| Actin |  |

| 0 100 200 400(nM) | 0 80 160 320(nM) |
| --- | --- |
| Flavopiridol | Flavopiridol |

FIGURE 4 – The apoptotic effects of flavopiridol via mitochondrial pathway in the ADR clones of OS and EFTs. (a) After the treatment of parental (P) or ADR cells of MNNG and WE-68 (5 × 107 cells) with flavopiridol for 24 hr, the cytosolic extracts were obtained and subjected to Western blot analysis as described in Material and methods. Actin was used as the internal control. (b) The ADR clones of OS and EFTs were treated with various concentrations of flavopiridol for 24 hr. The whole cell lysates were prepared and Western blot analysis was carried out using anti-p53, Bax, Bcl-xL, Bcl-2, and actin antibodies.

FMK efficiently inhibited flavopiridol-induced caspase-3 activation and cleavage of PARP in MNNG/ADR cells. These results revealed that flavopiridol could induce caspase-dependent apoptosis in the drug-resistant OS and EFTs clones, and that caspase-3 inhibitor, but not caspase-8 inhibitor, could prevent the cleavage of caspase-3 and the activation of PARP.

The apoptotic effect of flavopiridol was mainly mediated by mitochondrial pathway in the ADR clones of OS and EFTs

We next investigated whether the activation of caspase-9 and caspase-3 were attributed to the mitochondrial injury, which could lead to release of cytochrome c. Treatments of parental and ADR clones of OS and EFTs with 400 and 320 nM flavopiridol resulted in the expression of cytochrome c in the cytosolic fractions of the treated cells (Fig. 4a). It is reported that disruption of the balance between proapoptotic and antiapoptotic proteins, e.g. altered Bax/ Bcl-2 ratio, is a precursor for the release of cytochrome c from mitochondria,31 and that Bax gene is a target of p53 and can be regulated by p53 via transcriptional-dependent32 or independent mechanisms.33 In the present study, as shown in Figure 4b, the treatments of MNNG/ADR and WE-68/ADR cells with flavopiridol resulted in a decrease in the Bcl-2 and Bcl-xL expression in a dose-dependent manner. On the other hand, flavopiridol dose-dependently increased Bax and p53 expression in WE-68/ADR cells, but not in MNNG/ADR cells. This difference in response may relate to the difference in p53 status, which is wild-type in WE-68 and mutant in MNNG.

Flavopiridol inhibited the growth of the drug-resistant OS and EFTs tumors in mice

Since flavopiridol displayed antiproliferative and apoptotic effects on ADR clones of OS and EFTs in vitro, we set out to investigate the antiproliferative activity of flavopiridol in vivo.
